Galen Robotics, a Baltimore, Maryland-based surgical robotics company, completed the 1st close for a Series A round with $15m in funding.
Backers included Ambix Healthcare Partners.
The Series A helped complete the final robot prototype, and submission to FDA. Funds will also be used to develop a clinical sales team, expand engineering, grow product development, and develop surgeon training programs.
Led by Bruce Lichorowic, President and Chief Executive Officer, Galen Robotics has submitted a new collaborative soft tissue surgical robot, intended to address unmet needs in the market, to FDA for consideration. Termed Digital-Surgery-as-a-Service, the company offers a new approach to surgical robotics, clearing the way to capture surgical data and promote continuous improvements of surgical techniques, outcomes, and the training of residents.
Galen was founded in 2016 to commercialize the research originating from Johns Hopkins University. Once cleared, the robot is intended for minimally invasive procedures and is envisioned to aid surgeons with very little disturbance to current surgical workflows. Galen’s initial indications will focus on laryngological procedures. Future clearances will expand the scope of the platform into ENT, neurosurgery, spine, and cardiothoracic procedures.
FinSMEs
01/11/2022